Tags

Type your tag names separated by a space and hit enter

Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole.
Am J Gastroenterol. 1999 Jul; 94(7):1782-9.AJ

Abstract

OBJECTIVE

Because improvement in quality of life (QoL) is an important therapeutic goal in patients with heartburn but without esophagitis, the aim of the present study was to compare the impact of omeprazole 20 mg or 10 mg daily with that of placebo on QoL in patients with heartburn as the predominant symptom.

METHODS

QoL was measured at baseline and after 4 wk using two validated questionnaires, the Psychological General Well-Being (PGWB) index and the Gastrointestinal Symptom Rating Scale.

RESULTS

The two questionnaires were completed by 163 patients in the omeprazole 20 mg group, 163 in the omeprazole 10 mg group, and 82 in the placebo group. The reflux dimension of the Gastrointestinal Symptom Rating Scale showed a significant improvement in terms of reflux symptoms on omeprazole 20 mg versus omeprazole 10 mg and placebo, and on omeprazole 10 mg compared with placebo. The total score of the PGWB index improved significantly more on both doses of omeprazole than on placebo. The mean scores rose from 96.8 to 103.9 on omeprazole 20 mg, from 98.4 to 106.0 on omeprazole 10 mg, and from 98.0 to 100.6 on placebo. All dimensions of the PGWB index improved on treatment with omeprazole, but the improvements were most pronounced in the dimensions depicting anxiety, depressed mood, and self-control.

CONCLUSIONS

It is concluded that treatment with omeprazole 20 mg and omeprazole 10 mg restores QoL to a level comparable with that observed in a healthy population.

Authors+Show Affiliations

Department of Medicine, Odense University Hospital, Denmark.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10406235

Citation

Havelund, T, et al. "Quality of Life in Patients With Heartburn but Without Esophagitis: Effects of Treatment With Omeprazole." The American Journal of Gastroenterology, vol. 94, no. 7, 1999, pp. 1782-9.
Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol. 1999;94(7):1782-9.
Havelund, T., Lind, T., Wiklund, I., Glise, H., Hernqvist, H., Lauritsen, K., Lundell, L., Pedersen, S. A., Carlsson, R., Junghard, O., Stubberöd, A., & Anker-Hansen, O. (1999). Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. The American Journal of Gastroenterology, 94(7), 1782-9.
Havelund T, et al. Quality of Life in Patients With Heartburn but Without Esophagitis: Effects of Treatment With Omeprazole. Am J Gastroenterol. 1999;94(7):1782-9. PubMed PMID: 10406235.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. AU - Havelund,T, AU - Lind,T, AU - Wiklund,I, AU - Glise,H, AU - Hernqvist,H, AU - Lauritsen,K, AU - Lundell,L, AU - Pedersen,S A, AU - Carlsson,R, AU - Junghard,O, AU - Stubberöd,A, AU - Anker-Hansen,O, PY - 1999/7/16/pubmed PY - 1999/7/16/medline PY - 1999/7/16/entrez SP - 1782 EP - 9 JF - The American journal of gastroenterology JO - Am J Gastroenterol VL - 94 IS - 7 N2 - OBJECTIVE: Because improvement in quality of life (QoL) is an important therapeutic goal in patients with heartburn but without esophagitis, the aim of the present study was to compare the impact of omeprazole 20 mg or 10 mg daily with that of placebo on QoL in patients with heartburn as the predominant symptom. METHODS: QoL was measured at baseline and after 4 wk using two validated questionnaires, the Psychological General Well-Being (PGWB) index and the Gastrointestinal Symptom Rating Scale. RESULTS: The two questionnaires were completed by 163 patients in the omeprazole 20 mg group, 163 in the omeprazole 10 mg group, and 82 in the placebo group. The reflux dimension of the Gastrointestinal Symptom Rating Scale showed a significant improvement in terms of reflux symptoms on omeprazole 20 mg versus omeprazole 10 mg and placebo, and on omeprazole 10 mg compared with placebo. The total score of the PGWB index improved significantly more on both doses of omeprazole than on placebo. The mean scores rose from 96.8 to 103.9 on omeprazole 20 mg, from 98.4 to 106.0 on omeprazole 10 mg, and from 98.0 to 100.6 on placebo. All dimensions of the PGWB index improved on treatment with omeprazole, but the improvements were most pronounced in the dimensions depicting anxiety, depressed mood, and self-control. CONCLUSIONS: It is concluded that treatment with omeprazole 20 mg and omeprazole 10 mg restores QoL to a level comparable with that observed in a healthy population. SN - 0002-9270 UR - https://www.unboundmedicine.com/medline/citation/10406235/Quality_of_life_in_patients_with_heartburn_but_without_esophagitis:_effects_of_treatment_with_omeprazole_ L2 - https://Insights.ovid.com/pubmed?pmid=10406235 DB - PRIME DP - Unbound Medicine ER -